Disease relevance of C12425

• New anthracycline antibiotics, identified as epsilon-rhodomycinone glycosides, were isolated from the culture broth of a blocked mutant of beta-rhodomycin-producing Streptomyces violaceus A262 [1].

High impact information on C12425

• CONCLUSIONS: The high-yielding glycosylation of the aromatic polyketide epsilon-rhodomycinone using plasmid-borne deoxysugar biosynthesis genes proves that the minimal information for L-daunosamine biosynthesis and attachment in the heterologous host is encoded by the dnmLMJVUTS genes [2].
• A mathematical model of epsilon-rhodomycinone metabolism was constructed based on plausible assumptions concerning the kinetics of epsilon-rhodomycinone accumulation and catabolsim [3].
• In OC-NYH/VM cells, exhibiting multidrug resistance due to an altered topo II phenotype (at-MDR), cross-resistance was only seen to the RMN-containing drugs whereas no cross-resistance was seen to the non-DNA cleaving AKV-containing compounds [4].
• Carbons for the biosynthesis of epsilon-rhodomycinone, an anthracycline aglycone, from radiolabelled glucose were derived primarily from the Embden-Meyerhof-Parnas pathway, with a minor contribution from the pentose phosphate pathway [5].
• The conversion of epsilon-rhodomycinone to its 11-methyl ether via selective hydrolysis of the 4,6,7,11-tetraacetate is described [6].

Chemical compound and disease context of C12425

• Mutants of two of these groups produced compounds that had not yet been described in Streptomyces coeruleorubidus (aklavinone, 7-deoxyaklavinone, zeta-rhodomycinone and glycosides of epsilon-rhodomycinone) [7].

Associations of C12425 with other chemical compounds

• A two-plasmid system for the glycosylation of polyketide antibiotics: bioconversion of epsilon-rhodomycinone to rhodomycin D [2].

References